RBC Capital Maintains Sector Perform Rating on Regeneron Amid AbbVie's Acquisition of Apogee Therapeutics

RBC Capital has maintained a 'Sector Perform' rating for Regeneron Pharmaceuticals (REGN) with a $707 price target. The firm highlighted that AbbVie’s acquisition of Apogee Therapeutics could negatively impact Regeneron, as it introduces a stronger competitor in the dermatology market.

By Noor Ul Ain Rehman Sun, June 28, 2026 at 5:01 PM GMT+3 1 min read · Yahoo Finance · June 28, 2026, 14:01 UTC

Tickers: $ABBV $APGE $REGN

Topics: Investment Research M&A Impact Analysis Pharmaceuticals

Read the full article at Yahoo Finance

More World news

EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC
U.S. 30-Year Treasury Auction Yields Rise as Demand Weakens Seeking Alpha · November 12, 2026, 18:30 UTC
Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC